May 3, 2023 7:00 am EDT Study Demonstrates Use of DecisionDx®-Melanoma to Guide Treatment Decisions Resulted in Earlier Detection of Melanoma with Decreased Metastatic Tumor Burden Compared to Patients Without Surveillance Imaging Studies
Apr 28, 2023 7:00 am EDT Castle Biosciences Collaborates with IMPACT Melanoma to Provide Free Sunscreen to Cyclists Participating in the Bike MS: Texas MS 150 2023 Cycling Event
Apr 25, 2023 7:00 am EDT DecisionDx®-Melanoma Provides Improved Risk Stratification Over American Joint Committee on Cancer (AJCC) Staging Alone in Stage I Melanoma Patients
Apr 20, 2023 7:00 am EDT TissueCypher® Test Results Can Increase the Likelihood of Appropriate Management Decisions for Barrett’s Esophagus Patients with Low-Grade Dysplasia
Apr 19, 2023 7:00 am EDT Castle Biosciences to Release First Quarter 2023 Financial Results and Host Conference Call on Wednesday, May 3
Apr 12, 2023 7:00 am EDT Castle Biosciences to Present at the 22nd Annual Needham Virtual Healthcare Conference
Mar 18, 2023 7:00 am EDT Late-Breaking Data Presented at the 2023 AAD Annual Meeting Demonstrates Improved Accuracy of DecisionDx®-SCC in Predicting Metastatic Risk Over Traditional Staging Systems in Independent, Multi-Center Cohort Study
Mar 14, 2023 7:00 am EDT Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
Mar 10, 2023 7:00 am EST Castle Biosciences to Highlight Clinical Value of Its Skin Cancer Tests at the 2023 American Academy of Dermatology (AAD) Annual Meeting
